A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis

Inclusion Criteria:

- Age >=18 years at the time of signing informed consent.

- Meets American College of Rheumatology (ACR) classification of osteoarthritis (OA) and
have not responded to analgesics (level 1 and 2) or to non-steroidal anti-inflammatory
drugs (NSAIDs) for at least 10 days in the past 3 months.

- Active disease at screening and randomization with at least two swollen and tender
proximal interphalangeal (PIP) and/or distal interphalangeal (DIP) joints in the
affected hand.

- Signs of inflammation such as synovitis in the MRI scan of the affected hand.

- Must have a subject's self assessment of 24-hour average hand pain intensity at
baseline of at least '5' on an 11-point Numerical Rating Scale (NRS, 0-10).

- Weight >=45 kilogram (kg).

- Male or female subjects are eligible to participate so long as they meet and agree to
abide by the contraceptive criteria.

- Diffusing capacity of the lung for carbon monoxide (DLCO) >=70% predicted; forced
expiratory volume in 1 second (FEV1) >=80% predicted.

- No evidence of active or latent infection with Mycobacterium tuberculosis (TB).

Exclusion Criteria:

- Pregnant or lactating women.

- History of any clinically significant inflammatory disease other than inflammatory
HOA, especially, but not limited to, rheumatoid arthritis or spondylarthropathies.

- Diagnosis of rheumatoid arthritis, fibromyalgia, gout, calcium pyrophosphate
deposition disease (CPPD), pseudogout, hemochromatosis or other inflammatory
rheumatological or autoimmune disorders.

- Clinical suspicion of, or previous investigation for CPPD or pseudogout, or history of
chondrocalcinosis.

- Any injury, medical or surgical procedure to the affected joint(s) that may interfere
with evaluation of the target HOA joint(s).

- History of infected joint prosthesis at any time, with the prosthesis still in situ.
History of leg ulcers, catheters, chronic sinusitis or recurrent chest or urinary
tract infections.

- Any surgical procedure, including bone or joint surgery/synovectomy within 12 weeks
prior to Day 1 or any planned surgery within the duration of the study or follow-up
period.

- History of any respiratory disease which (in the opinion of the investigator) would
compromise subject safety or the ability of the subject to complete the study (e.g.
significant interstitial lung disease, such as pulmonary fibrosis, chronic obstructive
pulmonary disease (COPD), moderate-severe asthma, bronchiectasis, previous pulmonary
alveolar proteinosis [PAP]).

- Clinically-significant or unstable (in the opinion of the investigator) persistent
cough or dyspnea that is unexplained.

- Significant unstable or uncontrolled acute or chronic disease which, in the opinion of
the investigator, could confound the results of the study or put the subject at undue
risk.

- A history of malignancy.

- Hereditary or acquired immunodeficiency disorder, including immunoglobulin deficiency.

- Current/previous Hepatitis B virus (HBV), Hepatitis C virus (HCV) or human
immunodeficiency virus (HIV) 1 or 2 infection.